Patient Amgen Inc. (NASDAQ: AMGN)shareholders have seen the stock quadruple in price over the past decade, plus they've enjoyed one of the fastest-growing dividends in biopharma. Now that the company's launched a new migraine headache drug, investors are wondering if the former highflier can put on another memorable performance.
Is Amgen Inc. (AMGN) a Buy?
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться